{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:25Z","timestamp":1792047145025,"version":"4.4.0"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Elsbeth Bonhoff Stiftung","award":["Grant No. 244"],"award-info":[{"award-number":["Grant No. 244"]}]},{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OFIL-24-074"],"award-info":[{"award-number":["OFIL-24-074"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","award":["Clinician Scientist Programme"],"award-info":[{"award-number":["Clinician Scientist Programme"]}],"id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effects of 2 years of low-dose glucocorticoid (GC) treatment on bone mineral density and fracture risk in patients with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a protocolised (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/dx.doi.org\/10.17504\/protocols.io.6qpvr3ombvmk\/v1\">dx.doi.org\/10.17504\/protocols.io.6qpvr3ombvmk\/v1<\/jats:ext-link>\n                      ) systematic literature review and individual participant data meta-analysis of randomised trials in early and established RA, which compared GCs at \u22647.5\u2009mg prednisone equivalent\/day with placebo or standard of care. All patients could receive background treatment with disease-modifying antirheumatic drugs. Changes in lumbar spine and femoral bone density and participants with \u22651 clinical fracture over 2 years in intention-to-treat analyses were coprimary endpoints. Main analyses were based on one-stage models; I\u00b2 was estimated from two-stage models. Missing data were handled using multiple imputation. Several sensitivity analyses assessed the robustness of our results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 2336 articles, five out of six identified trials provided individual participant data (1112 participants). Greater bone loss was observed at the lumbar spine in the GC compared with the control group (\u22120.021\u2009g\/cm\u00b2; 95%\u2009CI \u22120.037 to \u22120.005; p=0.034; I\u00b2=31%) but not at the femur (0.004\u2009g\/cm\u00b2; 95%\u2009CI \u22120.008 to 0.016; p=0.47; I\u00b2=0%). Subgroup analyses did not reveal groups particularly susceptible to GC-induced bone loss at the lumbar spine. 35 participants experienced \u22651 fracture; fracture risk was comparable in both groups. Sensitivity analyses yielded consistent results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-dose GCs, used for 2 years to treat RA, lead to bone loss at the lumbar spine but not at the femur.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006615","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:27Z","timestamp":1778166927000},"page":"e006615","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-0597","authenticated-orcid":false,"given":"Andriko","family":"Palmowski","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany"},{"name":"Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"},{"name":"Epidemiology and Health Services Research, German Rheumatism Research Center (DRFZ), Institute of the Leibniz Association, Berlin, Germany"},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9, Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Haugegaard","sequence":"additional","affiliation":[{"name":"Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-758X","authenticated-orcid":false,"given":"Ingi\u00e4ld","family":"Hafstr\u00f6m","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Rheumatology, Department of Medicine Huddinge, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bliddal","sequence":"additional","affiliation":[{"name":"Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Oldenkott","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Wassenberg","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ratingen, Ratingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[{"name":"Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kirwan","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"},{"name":"Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany"},{"name":"Translational Rheumatology, German Rheumatism Research Center (DRFZ), A Leibniz Institute, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026050708151552000_12.2.e006615.1","doi-asserted-by":"crossref","first-page":"152535","DOI":"10.1016\/j.semarthrit.2024.152535","article-title":"Initiation of glucocorticoids before entering rheumatology care associates with long-term glucocorticoid use in older adults with early rheumatoid arthritis: a joint analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) data","volume":"68","author":"Palmowski","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026050708151552000_12.2.e006615.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.718"},{"key":"2026050708151552000_12.2.e006615.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2026050708151552000_12.2.e006615.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026050708151552000_12.2.e006615.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916"},{"key":"2026050708151552000_12.2.e006615.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114579"},{"key":"2026050708151552000_12.2.e006615.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221957"},{"key":"2026050708151552000_12.2.e006615.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222339"},{"key":"2026050708151552000_12.2.e006615.9","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos Int"},{"key":"2026050708151552000_12.2.e006615.10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","article-title":"Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink","volume":"61","author":"Abtahi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026050708151552000_12.2.e006615.11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026050708151552000_12.2.e006615.12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ard.2025.10.008","article-title":"Confounding by indication in observational studies investigating glucocorticoid-associated adverse events in patients with rheumatoid arthritis: a systematic literature review including an assessment of E-values","volume":"85","author":"Palmowski","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026050708151552000_12.2.e006615.13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.7326\/M23-0192","article-title":"The effect of low-dose glucocorticoids over two years on weight and blood pressure in rheumatoid arthritis: individual patient data from five randomized trials","volume":"176","author":"Palmowski","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026050708151552000_12.2.e006615.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3656"},{"key":"2026050708151552000_12.2.e006615.15","doi-asserted-by":"crossref","unstructured":"Singer M , Webb AR , Singer M , et al . Miscellaneous drugs. In: Oxford Handbook of Critical Care. Oxford University Press, 2009.","DOI":"10.1093\/med\/9780199235339.001.0001"},{"key":"2026050708151552000_12.2.e006615.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026050708151552000_12.2.e006615.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7141"},{"key":"2026050708151552000_12.2.e006615.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030908"},{"key":"2026050708151552000_12.2.e006615.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.21421"},{"key":"2026050708151552000_12.2.e006615.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21298"},{"key":"2026050708151552000_12.2.e006615.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330302"},{"key":"2026050708151552000_12.2.e006615.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014050"},{"key":"2026050708151552000_12.2.e006615.23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/acr2.11334","article-title":"A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort","volume":"4","author":"Andersen","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026050708151552000_12.2.e006615.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1461-3","article-title":"Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry","volume":"19","author":"Black","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2026050708151552000_12.2.e006615.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003366","article-title":"Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting","volume":"9","author":"Delteil","year":"2023","journal-title":"RMD Open"},{"key":"2026050708151552000_12.2.e006615.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-015-0019-5"},{"key":"2026050708151552000_12.2.e006615.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220112"},{"key":"2026050708151552000_12.2.e006615.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.001"},{"key":"2026050708151552000_12.2.e006615.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218758"},{"key":"2026050708151552000_12.2.e006615.30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1876"},{"key":"2026050708151552000_12.2.e006615.31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s001980050166","article-title":"Vertebral bone mineral density, content and area in 8789 normal women aged 33-73 years who have never had hormone replacement therapy","volume":"9","author":"Shipman","year":"1999","journal-title":"Osteoporos Int"},{"key":"2026050708151552000_12.2.e006615.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"2026050708151552000_12.2.e006615.33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-023-03083-x","article-title":"Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study","volume":"25","author":"Palmowski","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026050708151552000_12.2.e006615.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502"},{"key":"2026050708151552000_12.2.e006615.35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050708151552000_12.2.e006615.36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050708151552000_12.2.e006615.37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5414\/CN108473","article-title":"Efficacy of calcitriol in treating glucocorticoid-induced osteoporosis in patients with nephrotic syndrome: an open-label, randomized controlled study","volume":"84","author":"Chen","year":"2015","journal-title":"Clin Nephrol"},{"key":"2026050708151552000_12.2.e006615.38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.1983.tb02989.x","article-title":"Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study","volume":"19","author":"Braun","year":"1983","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:30Z","timestamp":1778166930000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006615"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006615","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}